<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hemodialysis arteriovenous graft dysfunction and failure</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hemodialysis arteriovenous graft dysfunction and failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hemodialysis arteriovenous graft dysfunction and failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Allon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan D Maya, MD, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen D Dillavou, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2410795383"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemodialysis requires access to blood vessels capable of providing rapid extracorporeal blood flow. These requirements are currently best met by arteriovenous (AV) access. Although AV fistulas are preferred for hemodialysis, AV grafts are sometimes necessary but have higher failure rates. Failure can be related to stenotic lesions affecting the feeding arteries, within the graft or in the draining veins, including the central veins. AV graft failure can also be related to complications such as pseudoaneurysm or other conditions that lead to sacrifice of the graft.</p><p>The treatment of AV graft failure due to venous stenosis and thrombotic complications are reviewed here. Issues surrounding clinical monitoring and surveillance of AV grafts to prevent thrombosis are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/89537.html" rel="external">"Physical examination of the arteriovenous graft"</a> and  <a class="medical medical_review" href="/d/html/1965.html" rel="external">"Clinical monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis"</a>.)</p><p>The management of stenosis and thrombosis of hemodialysis AV fistulas is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/97013.html" rel="external">"Early evaluation of the newly created hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/d/html/1957.html" rel="external">"Failure of the mature hemodialysis arteriovenous fistula"</a>.)</p><p class="headingAnchor" id="H704912434"><span class="h1">AV GRAFT DYSFUNCTION AND FAILURE</span></p><p class="headingAnchor" id="H3737182082"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>When stenotic lesions (primarily neointimal hyperplasia) develop in association with an AV graft, it often results in thrombosis. More than 90 percent of thrombosed AV grafts have a stenotic lesion, suggesting that such an anatomic abnormality is required for AV graft thrombosis. The majority of AV grafts develop stenosis or thrombosis. Among 649 patients with new AV grafts enrolled in the Dialysis Access Consortium (DAC) Study, 77 percent developed stenosis or thrombosis within the first year [<a href="#rid1">1</a>]. Similarly, among 201 patients with a new AV graft enrolled in the Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study, 62 percent developed stenosis or thrombosis within one year [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H549425723"><span class="h2">Etiology</span></p><p class="headingAnchor" id="H349842688"><span class="h3">Immediate</span><span class="headingEndMark"> — </span>Immediate failure of AV grafts following their creation is usually due to technical issues, often related to creation of an inadequate anastomosis as a result of severe arterial calcification. A large, single-center study observed immediate failure in 5.8 percent of upper extremity AV grafts and 12.7 percent of thigh grafts [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a>.) </p><p class="headingAnchor" id="H363177377"><span class="h3">Delayed</span><span class="headingEndMark"> — </span>AV graft failure beyond the postoperative period (delayed graft failure) is typically related to stenotic vascular lesions, most commonly affecting the venous outflow anastomosis due to neointimal hyperplasia. Critical stenosis can lead to sudden AV graft thrombosis. AV grafts less commonly fail due to infection. In a large single-center observational study of 310 AV grafts, 80 percent of graft failures were due to thrombosis, 14 percent were due to infection, and 3 percent were due to a large pseudoaneurysm with impending rupture. The remainder (2 percent) were caused by intractable central vein stenosis requiring AV graft ligation, and distal ischemia (steal syndrome) [<a href="#rid4">4</a>]. (See <a class="local">'Treatment of stenosis'</a> below and  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access", section on 'Lesions unique to AV grafts'</a> and  <a class="medical medical_review" href="/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a>.)</p><p>Some patients with thrombosis have an underlying hypercoagulable state as a cause for AV graft thrombosis [<a href="#rid5">5-8</a>]. (See <a class="local">'Hypercoagulable evaluation'</a> below.)</p><p class="headingAnchor" id="H1404642931"><span class="h1">CLINICAL PRESENTATION AND EVALUATION</span><span class="headingEndMark"> — </span>Most cases of AV graft thrombosis are preceded by rapidly progressive stenosis at the vein-graft anastomosis that can be documented by access surveillance or clinical monitoring. However, up to 25 percent of AV grafts clot fairly abruptly without prior indication of critical AV graft stenosis. (See  <a class="medical medical_review" href="/d/html/89537.html" rel="external">"Physical examination of the arteriovenous graft"</a> and  <a class="medical medical_review" href="/d/html/1965.html" rel="external">"Clinical monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis"</a>.)</p><p class="headingAnchor" id="H2680304795"><span class="h2">Abnormalities on clinical monitoring</span><span class="headingEndMark"> — </span>For patients with an abnormal clinical examination or abnormalities on monitoring and surveillance, the cause of the problem may be obvious with physical examination [<a href="#rid9">9</a>]. </p><p>In one review, clinical monitoring tools included abnormal physical examination (absent thrill, abnormal graft auscultation, or edema distal to the graft); abnormalities related to the dialysis session (difficulty in cannulation, aspiration of clots, inability to achieve the target dialysis blood flow, prolonged bleeding from the needle sites); and an unexplained, sustained fall (&gt;0.2 units) in delivered Kt/V, despite following a constant dialysis prescription [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis", section on 'Kt/V'</a>.)</p><p>Detection of one of these abnormalities led to routine angiograms, and, in 69 percent of cases, a lesion requiring angioplasty was detected. In a single-center randomized trial, the treatment arm undergoing clinical monitoring without ultrasound surveillance underwent 76 angioplasty procedures [<a href="#rid11">11</a>]. These were prompted by an abnormality in physical examination in 21 percent, abnormalities related to the dialysis session in 49 percent, and an unexplained decrease of Kt/V in 30 percent. Even in the group undergoing duplex ultrasound surveillance, 24 percent of the angioplasties were still prompted by abnormalities that arose during clinical monitoring. </p><p class="headingAnchor" id="H4089482630"><span class="h2">Evaluation of stenotic lesions</span><span class="headingEndMark"> — </span>In agreement with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, we define a clinically significant stenosis in an AV graft as a greater than 50 percent diameter narrowing in conjunction with the abnormal clinical findings, such as decreasing intragraft blood flow (less than 600 mL/min) or elevated static pressure within the graft [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/d/html/1965.html" rel="external">"Clinical monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis"</a>.) </p><p>Most AV grafts requiring treatment have only one stenotic site, but up to 30 percent can have two or more stenotic sites. In one study, more than 60 percent of stenotic lesions were located at the venous anastomosis and approximately 20 percent in draining peripheral veins [<a href="#rid10">10</a>]. The remainder of stenotic lesions occur within the body of the graft (ie, intragraft; 11 percent), in the central veins (7 to 8 percent), or at the arterial anastomosis (1.5 to 2 percent). Affected sites of associated stenotic lesions in AV grafts, in order of frequency (highest first), include [<a href="#rid14">14,15</a>] (see  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access", section on 'Sites of stenotic lesions'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Venous anastomotic stenosis – Approximately two thirds of reported venous stenosis lesions occur at the anastomosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intragraft stenosis – Unlike stenotic lesions occurring at other sites, which are due to neointimal hyperplasia, areas of narrowing within the AV graft are the result of the deposition of fibrin, lipid, and cellular debris. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral draining vein stenosis – Stenotic lesions can occur in draining veins other than venous anastomosis. In association with AV grafts, these are primarily the result of blood flow turbulence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central vein stenosis – The prevalence of central vein stenosis associated with AV grafts parallels the use of central catheters or other indwelling central venous devices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arterial stenosis – Stenotic lesions of the "feeding" arteries can also occur. In one review, 29 percent of AV grafts were affected, with the artery-graft anastomosis affected in 24 percent of cases [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H1306049893"><span class="h2">Hypercoagulable evaluation</span><span class="headingEndMark"> — </span>Among patients with very early (within 24 to 48 hours of surgery) or recurrent AV graft thrombosis in the absence of underlying stenosis, we initiate an evaluation for a coagulation abnormality or hypercoagulable state given that such patients are at increased risk of abnormalities [<a href="#rid6">6-8,17</a>]. As an example, antiphospholipid antibodies (aPLs) such as lupus anticoagulants (LAs) and anticardiolipin antibodies (aCLs) increase the risk of access thrombosis [<a href="#rid6">6-8</a>]. A report of 97 patients on maintenance hemodialysis noted that those with LA activity (16.5 percent) had a higher frequency of vascular access thrombosis than patients without an LA (62 versus 26 percent) [<a href="#rid6">6</a>].</p><p>In general, the assessment should include an evaluation for abnormalities in protein S, protein C, and antithrombin-3 as well as the presence of aPL. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a> and  <a class="medical medical_review" href="/d/html/1354.html" rel="external">"Protein C deficiency"</a> and  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a>.)</p><p class="headingAnchor" id="H852999487"><span class="h1">TREATMENT OF STENOSIS</span><span class="headingEndMark"> — </span>Underlying stenosis of an arteriovenous (AV) graft is an important predictor of thrombosis. The treatment of clinically significant stenosis of AV grafts is important clinically because it reduces vascular morbidity (via elective versus emergency repairs), preserves future access sites, and decreases the requirement of catheter placement and the associated adverse risks of catheter use [<a href="#rid18">18,19</a>]. </p><p>Stenotic lesions can be treated percutaneously with angioplasty (and stenting, when indicated) or with surgery. Some AV graft lesions may respond better with surgical revision. For patients identified with stenosis of hemodialysis AV grafts, we recommend percutaneous angioplasty, rather than surgery as the initial procedure. Lesions unsuitable for percutaneous transluminal angioplasty or that have failed angioplasty/stenting treatment can be referred for surgical revision. The use of stents following failed angioplasty is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access"</a>.)</p><p>Definitions for the hemodialysis access time points used in describing outcomes (eg, primary patency, assisted primary patency, postintervention patency) are provided in the figure (<a class="graphic graphic_figure graphicRef115040" href="/d/graphic/115040.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef70111" href="/d/graphic/70111.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3641599812"><span class="h2">Preemptive angioplasty</span><span class="headingEndMark"> — </span>Because it is safe, effective, and easily performed, we suggest preemptive angioplasty as the initial treatment of choice for the treatment of clinically significant stenosis affecting AV grafts to prevent thrombosis and/or failure of the vascular access [<a href="#rid11">11,14,20-24</a>]. Correcting the stenosis may decrease the risk of thrombosis and improve graft patency; however, randomized trials have not proven this to be the case (<a class="graphic graphic_figure graphicRef110941" href="/d/graphic/110941.html" rel="external">figure 2</a>) [<a href="#rid25">25,26</a>]. Representative studies that illustrate this point are reviewed briefly below for AV grafts. The indications and benefits of percutaneous angioplasty are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access"</a> and  <a class="medical medical_review" href="/d/html/1911.html" rel="external">"Techniques for angioplasty of the arteriovenous hemodialysis access"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>In a small trial, 21 patients with &gt;50 percent AV graft stenosis who had never undergone any procedure following graft placement were randomly assigned to no treatment (13 cases) or angioplasty (8 cases) [<a href="#rid27">27</a>]. In the treatment group, patency was significantly prolonged, and the thrombosis rate was significantly decreased compared with no preemptive treatment (0.10 versus 0.44 per patient-dialysis years). The angioplasty group received an average of 3.4 treatments per patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Over an eight-year period in one study, an intensive graft maintenance protocol using angioplasty reduced the thrombosis rate by 70 percent [<a href="#rid28">28</a>]. During this period, there was also a nearly eightfold decrease in the access replacement rate. The average age of usable AV grafts increased from approximately two to three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, a graft surveillance program using angioplasty decreased the graft thrombosis rate from 48 to 17 percent over a six-year period [<a href="#rid29">29</a>]. Repeated angioplasty treatments were required. The primary graft patency rate was 23 percent, while the assisted primary patency rate at one year was 68 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cumulative patency of 192 AV grafts was evaluated for two screening protocols with intervention performed for abnormal findings [<a href="#rid30">30</a>]. Patients either had traditional screening consisting of regular AV graft examination and monitoring of venous pressure or traditional screening plus ultrasound examinations every three months. The secondary cumulative AV access patency was significantly longer in group 1 compared with group 2 at 6, 12, and 24 months follow-up. The number of interventions per graft in groups 1 and 2 were 2.1 and 1.3, respectively, a difference that was not significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 112 hemodialysis patients, patients were randomly assigned to monthly vascular access blood flow surveillance plus standard surveillance (dynamic venous pressure and physical examination) or standard surveillance alone, with only the blood flow group referred for angiography and angioplasty for stenosis greater than 50 percent [<a href="#rid25">25</a>]. There were no differences in time to graft thrombosis or time to graft loss between the groups, suggesting that prospective monitoring plus preemptive angioplasty did not provide any benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in which monitoring was performed using monthly static venous pressure/systolic blood pressure ratios, 64 patients were randomly assigned to observation if the monthly ratio was elevated (≥0.4) and followed by angioplasty of any identified stenoses [<a href="#rid26">26</a>]. Treatment in the observation group was only performed for thrombosis of access. Graft survival was similar in both groups.</p><p></p><p class="headingAnchor" id="H4023729366"><span class="h2">Surgical revision</span><span class="headingEndMark"> — </span>Compared with angioplasty, surgery is less desirable as the initial procedure to manage stenotic lesions associated with AV grafts because although the lesion is eliminated, new lesions frequently emerge over time and, with repeated surgery, potential venous access sites are lost. As an example, even a patch angioplasty results in the loss of a small portion of vein. Additional adverse effects include postoperative pain and the occasional need for a temporary central catheter access following the operation. Nevertheless, there are certain lesions that may not respond to angioplasty or are unsuitable for angioplasty. These should be referred for surgical revision. As an example, a tight stenosis associated with a previous thrombosis tends to respond poorly to angioplasty and generally requires surgical correction. One study found that thrombosed grafts with unsuccessful percutaneous thrombectomy almost always (92 percent of cases) have a stenotic lesion at a location other than the venous anastomosis [<a href="#rid31">31</a>]. In addition, following an unsuccessful percutaneous graft thrombectomy, successful salvage by surgical revision was feasible in only 8 percent of cases [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access", section on 'Sites of stenotic lesions'</a>.) </p><p class="headingAnchor" id="H402952213"><span class="h1">TREATMENT OF THROMBOSIS</span><span class="headingEndMark"> — </span>There is no single best treatment for a thrombosed arteriovenous (AV) graft. Options include percutaneous or surgical thrombectomy. The approach chosen is largely based on local practice and expertise [<a href="#rid12">12</a>]. At the authors' institution, thrombosed AV grafts are most commonly treated percutaneously with thrombectomy in conjunction with balloon angioplasty of any identified underlying stenotic lesions. However, surgical thrombectomy and revision are used for grafts that thrombose within one month of their creation, or in cases for which the percutaneous approach is unsuccessful (ie, stenosis refractory to angioplasty, rapid recurrence of thrombosis).</p><p class="headingAnchor" id="H1904718984"><span class="h2">Percutaneous thrombolysis</span><span class="headingEndMark"> — </span>With a percutaneous approach, either pharmacologic agents, mechanical clot disruption, or a combination (pharmacomechanical thrombolysis) may be used, provided there are no contraindications to thrombolytic therapy (such as recent surgery, a bleeding disorder, a recent bleeding episode, or severe hypertension). If flow in the graft is restored, a fistulogram can then be performed to identify any associated stenoses, which can be treated with angioplasty [<a href="#rid17">17,32-37</a>]. If a percutaneous approach is not successful or deemed inappropriate, surgical thrombectomy and revision may be necessary. (See <a class="local">'Surgical thrombectomy'</a> below.)</p><p>The initial experience using thrombolytic agents, such as urokinase and streptokinase, yielded disappointing results [<a href="#rid38">38</a>]. However, subsequent dosing adjustments and technical advances have improved the success rate and reduced the incidence of bleeding [<a href="#rid39">39,40</a>]. As an example, use of the pulse-spray technique, which combines thrombolytic therapy with mechanical clot disruption, rapidly established access patency in over 90 percent of cases with minimal complications [<a href="#rid39">39</a>]. Fifty percent of these fistulas remained patent at one year. Although not available in all centers, the most common thrombolytic agent used is <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> [<a href="#rid41">41,42</a>]. Alteplase is delivered into the entire portion of the thrombosed access using a 4 Fr (French) catheter. The operator waits at least 15 to 30 minutes before proceeding to clot removal and subsequent angioplasty of the stenotic lesion. Care must be taken since the thrombolytic agent can be inadvertently delivered directly into the systemic circulation [<a href="#rid43">43,44</a>]. </p><p>Mechanical thrombolysis using specialized devices has been reported without use of any lytic agent. As examples, one study found that the Amplatz thrombectomy device and pulse-spray pharmacomechanical thrombolysis were similarly successful in recanalizing thrombosed grafts, with comparable primary patency rates [<a href="#rid45">45</a>]. Another study found similar technical success for mechanical clot disruption alone compared with pharmacomechanical clot disruption using urokinase, but AV grafts treated with mechanical thrombectomy had improved long-term patency [<a href="#rid46">46</a>]. </p><p>A concern with percutaneous thrombolysis is the potential for clinically significant pulmonary emboli. In a review of over 650 cases, only one clinically apparent pulmonary embolus was documented (the symptoms of which resolved within 24 hours), and two patients developed transient chest pain of undetermined etiology [<a href="#rid46">46</a>]. A second well-designed study compared ventilation-perfusion scintigraphy before and after thrombolysis [<a href="#rid47">47</a>]. In this study, 13 patients had clotted AV grafts, 9 of whom underwent mechanical thrombolysis alone, and the remainder had pharmacomechanical thrombolysis with urokinase. No patient had radiographic evidence of pulmonary embolism. To reduce the possibility of large pulmonary emboli, a device has been developed that consists of a high-speed rotating cam tip that pulverizes the clot into tiny particles.</p><p class="headingAnchor" id="H2572223932"><span class="h2">Surgical thrombectomy</span><span class="headingEndMark"> — </span>Surgical thrombectomy is a relatively quick procedure, has a very low complication rate, and is initially successful in 90 percent of cases. However, failure to correct the underlying outflow stenosis, which can be accomplished using percutaneous or open techniques, will lead to rapid rethrombosis.</p><p>Although not adequately studied, it appears that surgical treatment for AV graft thrombosis is comparable to percutaneous intervention. This was shown in a meta-analysis of eight randomized studies, in which similar results with both techniques were reported for studies published after 2002 [<a href="#rid48">48</a>]. The primary patency of AV grafts after surgical thrombectomy and angioplasty ranged from 30 to 60 percent at three months and 10 to 40 percent at six months [<a href="#rid49">49-51</a>].</p><p>Surgical thrombectomy involves making a small incision overlying, typically, the venous outflow limb of the AV graft and then using a Fogarty embolectomy catheter to sequentially remove clot first from the graft and then from the venous and arterial anastomoses. A graft study (graftogram, on-table duplex ultrasound) can be performed to determine if any significant inflow or outflow stenoses are present. These can be managed using open surgical revision (patch angioplasty, jump graft). With the availability of intraoperative fluoroscopy imaging (mobile C-arm, hybrid operating room), balloon angioplasty of any identified lesions can be performed just as would be performed in an interventional radiology suite. Alternatively, in the absence of intraoperative imaging, vascular dilators can be passed through at least the venous anastomosis, the most likely site of stenosis. Interrogation of the arterial anastomosis may require extension of the incision or a separate incision and arterial limb graftotomy. </p><p class="headingAnchor" id="H4176657384"><span class="h2">Antithrombotic therapy</span><span class="headingEndMark"> — </span>Following treatment of AV graft thrombosis, recurrent thrombosis is common and, although mechanical treatment of the underlying lesion using angioplasty reduces it, does not eliminate the lesion. Medical therapies are primarily aimed at lessening neointimal hyperplasia or treating hypercoagulability. </p><p>Although entirely opinion based, we consider administering <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> to selected patients with a hypercoagulable state. Specific management issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/1950.html" rel="external">"Overview of hemodialysis arteriovenous graft maintenance and thrombosis prevention"</a>.)</p><p class="headingAnchor" id="H3072368130"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Reasonable outcome goals following treatment for graft thrombosis are as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>A success rate, defined by the ability to use the graft at least once postprocedure, of 85 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary patency of 40 percent at three months after percutaneous thrombectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary patency of 50 and 40 percent at 6 and 12 months after surgical thrombectomy, respectively.</p><p></p><p>Terminology used to describe postintervention patency rates following percutaneous intervention for hemodialysis arteriovenous access in accordance with the Society of Interventional Radiology (SIR) reporting standards is given in the table (<a class="graphic graphic_table graphicRef70111" href="/d/graphic/70111.html" rel="external">table 1</a>) [<a href="#rid52">52</a>].</p><p>The overall patency following treatment of arteriovenous (AV) graft stenosis or AV graft thrombosis is briefly reviewed below [<a href="#rid53">53-56</a>].</p><p class="headingAnchor" id="H2771343101"><span class="h2">Overall patency following treatment of stenosis</span><span class="headingEndMark"> — </span>Preemptive angioplasty of the stenotic lesion in AV grafts is not a permanent treatment. Even after an excellent technical success (visual inspection at time of the angioplasty), which is close to 100 percent, the low rates of access patency for AV grafts at 3, 6, and 12 months are discouraging [<a href="#rid10">10,25,49,57-60</a>]. The patency rates for specific anatomic lesions are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access"</a>.)</p><p class="headingAnchor" id="H3273641903"><span class="h2">Overall patency following treatment of thrombosis</span><span class="headingEndMark"> — </span>The overall primary patency after percutaneous thrombectomy is slightly better for AV grafts compared with AV fistulas (at six months, it is 25 to 40 percent for grafts compared with 20 to 40 percent for fistulas) [<a href="#rid49">49,61</a>]. The primary patency of the underlying stenotic lesion following thrombectomy is much worse. In a number of series, primary graft patency after thrombectomy and angioplasty was 37 to 63 percent at three months and 11 to 39 percent after six months [<a href="#rid39">39,46,59,62-67</a>]. A large observational study comparing more than 300 graft thrombectomies with more than 300 elective angioplasties performed at one large medical center observed a primary patency at six months of 19 percent after thrombectomy versus 51 percent after elective angioplasty [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H184412511"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/132674.html" rel="external">"Society guideline links: Hemodialysis vascular access"</a>.)</p><p class="headingAnchor" id="H381912240"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4414.html" rel="external">"Patient education: Hemodialysis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3822064725"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arteriovenous graft dysfunction</strong> – Arteriovenous (AV) graft dysfunction and failure is common. Immediate failure in the postoperative period is usually due to technical issues. AV graft dysfunction and failure beyond the postoperative period (ie, delayed graft failure) is predominantly related to stenotic vascular lesions. AV graft failure can also be related to complications such as infection, pseudoaneurysm, or other conditions that lead to sacrifice of the graft. (See <a class="local">'AV graft dysfunction and failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – For patients with an abnormal clinical examination or abnormalities on monitoring and surveillance, the cause of the problem may be obvious on physical examination of the AV graft. Most cases of AV graft thrombosis are preceded by progressive stenosis at the vein-graft anastomosis that can be documented by access surveillance or clinical monitoring. However, up to 25 percent of AV grafts clot fairly abruptly without prior indication of critical stenosis. (See <a class="local">'Clinical presentation and evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of stenosis</strong> – Although most AV grafts requiring treatment have only one stenotic site, up to 30 percent can have two or more stenotic sites. A clinically significant stenosis in an AV graft is defined as a greater than 50 percent narrowing of the diameter with abnormal clinical findings, such as decreasing intragraft blood flow (less than 600 mL/min) or elevated static pressure within the graft. Affected sites of associated stenotic lesions in AV grafts are listed above and described in more detail separately. (See <a class="local">'Evaluation of stenotic lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of stenosis</strong> – Stenotic vascular lesions can be treated percutaneously with angioplasty, or with surgery. For patients identified with stenosis of hemodialysis access grafts, we recommend preemptive percutaneous angioplasty rather than surgery as the initial procedure (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Lesions unsuitable for percutaneous transluminal angioplasty can be referred for surgical revision. Even with excellent technical success rates, which approach 100 percent, the low rates of AV graft patency are discouraging. (See <a class="local">'Treatment of stenosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of thrombosis</strong> – Once thrombosis of an AV graft has occurred, treatment options include percutaneous or surgical thrombectomy, in conjunction with angioplasty (balloon, patch) of any identified underlying stenotic lesions. The approach chosen is largely based upon local practice and expertise. Each institution should determine which initial approach is preferred. Following percutaneous thrombectomy, patency for AV grafts is slightly better compared with AV fistulas. Primary patency of the underlying stenotic lesion is much worse following thrombectomy compared with preemptive angioplasty. (See <a class="local">'Treatment of thrombosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360:2191.</a></li><li><a class="nounderline abstract_t">Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA 2012; 307:1809.</a></li><li><a class="nounderline abstract_t">Miller CD, Robbin ML, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. J Am Soc Nephrol 2003; 14:2942.</a></li><li><a class="nounderline abstract_t">Harms JC, Rangarajan S, Young CJ, et al. Outcomes of arteriovenous fistulas and grafts with or without intervention before successful use. J Vasc Surg 2016; 64:155.</a></li><li><a class="nounderline abstract_t">Klamroth R, Orlovic M, Fritsche I, et al. The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation. Vasa 2013; 42:32.</a></li><li><a class="nounderline abstract_t">Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48:794.</a></li><li><a class="nounderline abstract_t">Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26:347.</a></li><li><a class="nounderline abstract_t">Molino D, De Lucia D, Marotta R, et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005; 68:1223.</a></li><li><a class="nounderline abstract_t">Beathard GA. An algorithm for the physical examination of early fistula failure. Semin Dial 2005; 18:331.</a></li><li><a class="nounderline abstract_t">Maya ID, Oser R, Saddekni S, et al. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis 2004; 44:859.</a></li><li><a class="nounderline abstract_t">Robbin ML, Oser RF, Lee JY, et al. Randomized comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes. Kidney Int 2006; 69:730.</a></li><li><a class="nounderline abstract_t">Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis 2020; 75:S1.</a></li><li><a class="nounderline abstract_t">Paulson WD, Moist L, Lok CE. Vascular access surveillance: an ongoing controversy. Kidney Int 2012; 81:132.</a></li><li><a class="nounderline abstract_t">Beathard GA. Angioplasty for arteriovenous grafts and fistulae. Semin Nephrol 2002; 22:202.</a></li><li><a class="nounderline abstract_t">Kanterman RY, Vesely TM, Pilgram TK, et al. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 1995; 195:135.</a></li><li><a class="nounderline abstract_t">Asif A, Gadalean FN, Merrill D, et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 2005; 67:1986.</a></li><li><a class="nounderline abstract_t">Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis. Kidney Int 1999; 55:2078.</a></li><li><a class="nounderline abstract_t">McCarley P, Wingard RL, Shyr Y, et al. Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001; 60:1164.</a></li><li><a class="nounderline abstract_t">White JJ, Bander SJ, Schwab SJ, et al. Is percutaneous transluminal angioplasty an effective intervention for arteriovenous graft stenosis? Semin Dial 2005; 18:190.</a></li><li><a class="nounderline abstract_t">Lok CE, Bhola C, Croxford R, Richardson RM. Reducing vascular access morbidity: a comparative trial of two vascular access monitoring strategies. Nephrol Dial Transplant 2003; 18:1174.</a></li><li><a class="nounderline abstract_t">Maoz D, Reinitz R, Rimon U, et al. Hemodialysis graft flow surveillance with prompt corrective interventions improves access long-term patency. Clin Nephrol 2009; 71:43.</a></li><li><a class="nounderline abstract_t">Tessitore N, Lipari G, Poli A, et al. Can blood flow surveillance and pre-emptive repair of subclinical stenosis prolong the useful life of arteriovenous fistulae? A randomized controlled study. Nephrol Dial Transplant 2004; 19:2325.</a></li><li><a class="nounderline abstract_t">Ram SJ, Work J, Caldito GC, et al. A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int 2003; 64:272.</a></li><li><a class="nounderline abstract_t">Lumsden AB, MacDonald MJ, Kikeri D, et al. Prophylactic balloon angioplasty fails to prolong the patency of expanded polytetrafluoroethylene arteriovenous grafts: results of a prospective randomized study. J Vasc Surg 1997; 26:382.</a></li><li><a class="nounderline abstract_t">Moist LM, Churchill DN, House AA, et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 2003; 14:2645.</a></li><li><a class="nounderline abstract_t">Dember LM, Holmberg EF, Kaufman JS. Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. Kidney Int 2004; 66:390.</a></li><li><a class="nounderline abstract_t">Martin LG, MacDonald MJ, Kikeri D, et al. Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study. J Vasc Interv Radiol 1999; 10:389.</a></li><li><a class="nounderline abstract_t">Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 1995; 47:1364.</a></li><li><a class="nounderline abstract_t">Funaki B, Kim R, Lorenz J, et al. Using pullback pressure measurements to identify venous stenoses persisting after successful angioplasty in failing hemodialysis grafts. AJR Am J Roentgenol 2002; 178:1161.</a></li><li><a class="nounderline abstract_t">Malik J, Slavikova M, Svobodova J, Tuka V. Regular ultrasonographic screening significantly prolongs patency of PTFE grafts. Kidney Int 2005; 67:1554.</a></li><li><a class="nounderline abstract_t">Maya ID, Smith T, Young CJ, Allon M. Is surgical salvage of arteriovenous grafts feasible after unsuccessful percutaneous mechanical thrombectomy? Semin Dial 2008; 21:174.</a></li><li><a class="nounderline abstract_t">Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3:1.</a></li><li><a class="nounderline abstract_t">Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993; 21:457.</a></li><li><a class="nounderline abstract_t">Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney Int 1998; 54:1029.</a></li><li><a class="nounderline abstract_t">Hurt AV, Batello-Cruz M, Skipper BJ, et al. Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. Am J Surg 1983; 146:844.</a></li><li><a class="nounderline abstract_t">Palder SB, Kirkman RL, Whittemore AD, et al. Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985; 202:235.</a></li><li><a class="nounderline abstract_t">Lipari G, Tessitore N, Poli A, et al. Outcomes of surgical revision of stenosed and thrombosed forearm arteriovenous fistulae for haemodialysis. Nephrol Dial Transplant 2007; 22:2605.</a></li><li><a class="nounderline abstract_t">Young AT, Hunter DW, Castaneda-Zuniga WR, et al. Thrombosed synthetic hemodialysis access fistulas: failure of fibrinolytic therapy. Radiology 1985; 154:639.</a></li><li><a class="nounderline abstract_t">Valji K, Bookstein JJ, Roberts AC, Davis GB. Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialysis grafts: early and late clinical results. Radiology 1991; 178:243.</a></li><li><a class="nounderline abstract_t">Ahmed A, Shapiro WB, Porush JG. The use of tissue plasminogen activator to declot arteriovenous accesses in hemodialysis patients. Am J Kidney Dis 1993; 21:38.</a></li><li><a class="nounderline abstract_t">Schon D, Mishler R. Salvage of occluded autologous arteriovenous fistulae. Am J Kidney Dis 2000; 36:804.</a></li><li><a class="nounderline abstract_t">Cooper SG. Original report. Pulse-spray thrombolysis of thrombosed hemodialysis grafts with tissue plasminogen activator. AJR Am J Roentgenol 2003; 180:1063.</a></li><li><a class="nounderline abstract_t">Kinney TB, Valji K, Rose SC, et al. Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline. J Vasc Interv Radiol 2000; 11:1143.</a></li><li><a class="nounderline abstract_t">Trerotola SO, Johnson MS, Shah H, et al. Incidence and management of arterial emboli from hemodialysis graft surgical thrombectomy. J Vasc Interv Radiol 1997; 8:557.</a></li><li><a class="nounderline abstract_t">Sofocleous CT, Cooper SG, Schur I, et al. Retrospective comparison of the Amplatz thrombectomy device with modified pulse-spray pharmacomechanical thrombolysis in the treatment of thrombosed hemodialysis access grafts. Radiology 1999; 213:561.</a></li><li><a class="nounderline abstract_t">Beathard GA. Mechanical versus pharmacomechanical thrombolysis for the treatment of thrombosed dialysis access grafts. Kidney Int 1994; 45:1401.</a></li><li><a class="nounderline abstract_t">Petronis JD, Regan F, Briefel G, et al. Ventilation-perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts. Am J Kidney Dis 1999; 34:207.</a></li><li><a class="nounderline abstract_t">Tordoir JH, Bode AS, Peppelenbosch N, et al. Surgical or endovascular repair of thrombosed dialysis vascular access: is there any evidence? J Vasc Surg 2009; 50:953.</a></li><li><a class="nounderline abstract_t">Zaleski GX, Funaki B, Kenney S, et al. Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas. J Vasc Interv Radiol 1999; 10:129.</a></li><li><a class="nounderline abstract_t">Beathard GA, Welch BR, Maidment HJ. Mechanical thrombolysis for the treatment of thrombosed hemodialysis access grafts. Radiology 1996; 200:711.</a></li><li><a class="nounderline abstract_t">Ponikvar R. Surgical salvage of thrombosed arteriovenous fistulas and grafts. Ther Apher Dial 2005; 9:245.</a></li><li><a class="nounderline abstract_t">Gray RJ, Sacks D, Martin LG, et al. Reporting standards for percutaneous interventions in dialysis access. J Vasc Interv Radiol 2003; 14:S433.</a></li><li><a class="nounderline abstract_t">Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg 2003; 38:1005.</a></li><li><a class="nounderline abstract_t">Ethier J, Mendelssohn DC, Elder SJ, et al. Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2008; 23:3219.</a></li><li><a class="nounderline abstract_t">Pisoni RL, Young EW, Dykstra DM, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61:305.</a></li><li><a class="nounderline abstract_t">Pisoni RL. Vascular access use and outcomes: results from the DOPPS. Contrib Nephrol 2002; :13.</a></li><li><a class="nounderline abstract_t">Schwab SJ, Oliver MJ, Suhocki P, McCann R. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 2001; 59:358.</a></li><li><a class="nounderline abstract_t">Murray BM, Rajczak S, Ali B, et al. Assessment of access blood flow after preemptive angioplasty. Am J Kidney Dis 2001; 37:1029.</a></li><li><a class="nounderline abstract_t">Lilly RZ, Carlton D, Barker J, et al. Predictors of arteriovenous graft patency after radiologic intervention in hemodialysis patients. Am J Kidney Dis 2001; 37:945.</a></li><li><a class="nounderline abstract_t">Maya ID, Saddekni S, Allon M. Treatment of refractory central vein stenosis in hemodialysis patients with stents. Semin Dial 2007; 20:78.</a></li><li><a class="nounderline abstract_t">Jain G, Maya ID, Allon M. Outcomes of percutaneous mechanical thrombectomy of arteriovenous fistulas in hemodialysis patients. Semin Dial 2008; 21:581.</a></li><li><a class="nounderline abstract_t">Turmel-Rodrigues L, Pengloan J, Baudin S, et al. Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant 2000; 15:2029.</a></li><li><a class="nounderline abstract_t">Beathard GA. Thrombolysis versus surgery for the treatment of thrombosed dialysis access grafts. J Am Soc Nephrol 1995; 6:1619.</a></li><li><a class="nounderline abstract_t">Cohen MA, Kumpe DA, Durham JD, Zwerdlinger SC. Improved treatment of thrombosed hemodialysis access sites with thrombolysis and angioplasty. Kidney Int 1994; 46:1375.</a></li><li><a class="nounderline abstract_t">Sands JJ, Patel S, Plaviak DJ, Miranda CL. Pharmacomechanical thrombolysis with urokinase for treatment of thrombosed hemodialysis access grafts. A comparison with surgical thrombectomy. ASAIO J 1994; 40:M886.</a></li><li><a class="nounderline abstract_t">Trerotola SO, Lund GB, Scheel PJ Jr, et al. Thrombosed dialysis access grafts: percutaneous mechanical declotting without urokinase. Radiology 1994; 191:721.</a></li><li><a class="nounderline abstract_t">Trerotola SO, Vesely TM, Lund GB, et al. Treatment of thrombosed hemodialysis access grafts: Arrow-Trerotola percutaneous thrombolytic device versus pulse-spray thrombolysis. Arrow-Trerotola Percutaneous Thrombolytic Device Clinical Trial. Radiology 1998; 206:403.</a></li></ol></div><div id="topicVersionRevision">Topic 1971 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458364" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effect of dipyridamole plus aspirin on hemodialysis graft patency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550196" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27066945" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Outcomes of arteriovenous fistulas and grafts with or without intervention before successful use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23385224" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474666" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645540" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16105054" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076357" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An algorithm for the physical examination of early fistula failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492952" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vascular access stenosis: comparison of arteriovenous grafts and fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518328" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Randomized comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778223" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975864" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vascular access surveillance: an ongoing controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12012306" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Angioplasty for arteriovenous grafts and fistulae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892454" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840048" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10231476" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vascular access for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532113" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vascular access blood flow monitoring reduces access morbidity and costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934961" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Is percutaneous transluminal angioplasty an effective intervention for arteriovenous graft stenosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748352" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reducing vascular access morbidity: a comparative trial of two vascular access monitoring strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203549" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hemodialysis graft flow surveillance with prompt corrective interventions improves access long-term patency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280529" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Can blood flow surveillance and pre-emptive repair of subclinical stenosis prolong the useful life of arteriovenous fistulae? A randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787419" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308584" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prophylactic balloon angioplasty fails to prolong the patency of expanded polytetrafluoroethylene arteriovenous grafts: results of a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514744" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200448" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229464" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637266" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11959724" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Using pullback pressure measurements to identify venous stenoses persisting after successful angioplasty in failing hemodialysis grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780111" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Regular ultrasonographic screening significantly prolongs patency of PTFE grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18226010" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Is surgical salvage of arteriovenous grafts feasible after unsuccessful percutaneous mechanical thrombectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1391700" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vascular access: concepts for the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8488813" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Permanent vascular access: a nephrologist's view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767519" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hemodialysis access failure: a call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650773" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4015229" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vascular access for hemodialysis. Patency rates and results of revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517799" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcomes of surgical revision of stenosed and thrombosed forearm arteriovenous fistulae for haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969465" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Thrombosed synthetic hemodialysis access fistulas: failure of fibrinolytic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824582" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialysis grafts: early and late clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418624" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The use of tissue plasminogen activator to declot arteriovenous accesses in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007684" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Salvage of occluded autologous arteriovenous fistulae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12646455" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Original report. Pulse-spray thrombolysis of thrombosed hemodialysis grafts with tissue plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041470" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9232570" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence and management of arterial emboli from hemodialysis graft surgical thrombectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551242" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Retrospective comparison of the Amplatz thrombectomy device with modified pulse-spray pharmacomechanical thrombolysis in the treatment of thrombosed hemodialysis access grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072252" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mechanical versus pharmacomechanical thrombolysis for the treatment of thrombosed dialysis access grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430963" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ventilation-perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786244" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Surgical or endovascular repair of thrombosed dialysis vascular access: is there any evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10082098" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756920" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mechanical thrombolysis for the treatment of thrombosed hemodialysis access grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15966999" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgical salvage of thrombosed arteriovenous fistulas and grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514859" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reporting standards for percutaneous interventions in dialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14603208" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511606" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786113" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vascular access use in Europe and the United States: results from the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12101946" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Vascular access use and outcomes: results from the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135091" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325686" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Assessment of access blood flow after preemptive angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325676" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Predictors of arteriovenous graft patency after radiologic intervention in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17244127" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of refractory central vein stenosis in hemodialysis patients with stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000116" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Outcomes of percutaneous mechanical thrombectomy of arteriovenous fistulas in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096150" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749689" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thrombolysis versus surgery for the treatment of thrombosed dialysis access grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853796" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Improved treatment of thrombosed hemodialysis access sites with thrombolysis and angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555639" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacomechanical thrombolysis with urokinase for treatment of thrombosed hemodialysis access grafts. A comparison with surgical thrombectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8184052" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Thrombosed dialysis access grafts: percutaneous mechanical declotting without urokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457193" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of thrombosed hemodialysis access grafts: Arrow-Trerotola percutaneous thrombolytic device versus pulse-spray thrombolysis. Arrow-Trerotola Percutaneous Thrombolytic Device Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
